Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023)
Roivant Sciences' (ROIV) quarterly Net Equity Issued and Repurchased came in at $199.8 million in Q4 2023, up 110.93% YoY from $94.7 million in Q4 2022, and up 110.93% on a QoQ basis from $94.7 million in Q4 2022.
Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023) Analysis & Trends
Roivant Sciences (ROIV) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $199.8 million in Q4 2023.
- Quarterly Net Equity Issued and Repurchased rose 110.93% year-over-year to $199.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $294.6 million (changed N/A YoY) and the FY2024 annual result came in at $199.8 million, down 35.95% from the prior year.
- Net Equity Issued and Repurchased advanced to $199.8 million in Q4 2023, from $94.7 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $199.8 million in Q4 2023 to a low of $94.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 199.82 Mn |
| Dec 31, 2023 | 199.82 Mn |
| Dec 31, 2022 | 94.74 Mn |
| Dec 31, 2022 | 94.74 Mn |